BTIG raised the firm’s price target on Sophia Genetics (SOPH) to $8 from $7 and keeps a Buy rating on the shares. After having recently hosted two days of investor meetings with Sophia Genetics’ President and soon-to-be CEO Ross Muken, CFO George Cardoza and Head of Strategy Kellen Sanger, the firm reports that management “signaled confidence across the business.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- Sophia Genetics management to meet with Craig-Hallum
- Sophia Genetics management to meet with BTIG
- Sophia Genetics management to meet with Piper Sandler
- Sophia Genetics Earnings Call: Growth Surges, Losses Linger
- SOPHiA GENETICS: Clear Growth Inflection, Improving Margins, and Path to 2026 Profitability Support Buy Rating